Hepatitis

VIR201 data presented at conference

Published in Gene Therapy Weekly, March 11th, 2004

Virax Holdings, Ltd., announced that its research partner, the Australian National Centre for HIV Epidemiology and Clinical Research (NCHECR), presented data and released results of the recent clinical trial of Virax's immune-based therapy VIR201 at the prestigious 11th International Conference on Retroviruses and Opportunistic Infections in San Francisco, California.

"VIR201 is the first treatment of its kind in the world to show an ability to block the progression of this potentially deadly virus in HIV positive patients," said Professor David Cooper, NCHECR director.

"On the clinical evidence now available, VIR201 is one of the most promising...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-03-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry